- BLUE has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $202.6 million.
- BLUE is up 5.5% today from today's close.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in BLUE with the Ticky from Trade-Ideas. See the FREE profile for BLUE NOW at Trade-Ideas More details on BLUE: bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic and rare diseases. Currently there are 9 analysts that rate bluebird bio a buy, no analysts rate it a sell, and none rate it a hold. The average volume for bluebird bio has been 785,400 shares per day over the past 30 days. Bluebird bio has a market cap of $6.3 billion and is part of the health care sector and drugs industry. Shares are up 105.5% year-to-date as of the close of trading on Tuesday. EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates bluebird bio as a sell. The company's weaknesses can be seen in multiple areas, such as its feeble growth in its earnings per share, deteriorating net income and weak operating cash flow.